Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Natpara is a bioengineered replica of human parathyroid hormone that raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (ie, by converting 25 OH vitamin D to 1,25 OH2 vitamin D), and by increasing bone turnover which releases calcium into the circulation.

Natpara is only available through a Risk Evaluation and Mitigation Strategy (REMS) Program by a limited number of specialty pharmacies. Under the Natpara REMS Program, only certified healthcare providers can prescribe, and only certified pharmacies can dispense the product.

Continue Reading

Natpara is supplied in 25-mcg, 50-mcg, 75-mcg and 100-mcg strength cartridges in 2-count packages.

The FDA approved Natpara in January 2015. 

For more information call (855) NAT-PARA or visit

This article originally appeared on MPR